XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.2
Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
May 31, 2025
Dec. 31, 2024
Business Combination [Line Items]                  
Research and development       $ 4,048.0 $ 3,500.0 $ 7,669.0 $ 7,492.0    
Property, plant and equipment, net       25,236.0   $ 25,236.0     $ 23,779.0
Verona Pharma plc | Subsequent Event                  
Business Combination [Line Items]                  
Consideration transferred, asset acquisition (in dollars per depository share) $ 107                
Asset acquisition, share conversion, ordinary shares per depository shares (in shares) 8                
Consideration transferred, asset acquisition $ 10,000.0                
HRS-5346 , Jiangsu Hengrui Pharmaceuticals Co., Ltd.                  
Business Combination [Line Items]                  
Research and development       $ 200.0          
Jiangsu Hengrui Pharmaceuticals Co., Ltd.                  
Business Combination [Line Items]                  
Future contingent developmental milestone payments (up to)               $ 92.5  
Future regulatory milestone payments (up to)               177.5  
Maximum aggregate sales-based milestone payments               $ 1,500.0  
WuXi Vaccines' facility                  
Business Combination [Line Items]                  
Consideration transferred, asset acquisition   $ 437.0              
WuXi Vaccines' facility | Asset under Construction                  
Business Combination [Line Items]                  
Property, plant and equipment, net   $ 759.0              
Harpoon Therapeutics, Inc.                  
Business Combination [Line Items]                  
Asset acquisition, transaction costs     $ 56.0            
Consideration transferred, asset acquisition     $ 765.0            
Research and development             656.0    
Net assets acquired             $ 165.0